

Cite this: *Chem. Sci.*, 2021, 12, 14577

All publication charges for this article have been paid for by the Royal Society of Chemistry

# Deep generative design with 3D pharmacophoric constraints†

Fergus Imrie,<sup>a</sup> Thomas E. Hadfield,<sup>a</sup> Anthony R. Bradley<sup>b</sup>  
and Charlotte M. Deane<sup>a\*</sup>

Generative models have increasingly been proposed as a solution to the molecular design problem. However, it has proved challenging to control the design process or incorporate prior knowledge, limiting their practical use in drug discovery. In particular, generative methods have made limited use of three-dimensional (3D) structural information even though this is critical to binding. This work describes a method to incorporate such information and demonstrates the benefit of doing so. We combine an existing graph-based deep generative model, DeLinker, with a convolutional neural network to utilise physically-meaningful 3D representations of molecules and target pharmacophores. We apply our model, DEVELOP, to both linker and R-group design, demonstrating its suitability for both hit-to-lead and lead optimisation. The 3D pharmacophoric information results in improved generation and allows greater control of the design process. In multiple large-scale evaluations, we show that including 3D pharmacophoric constraints results in substantial improvements in the quality of generated molecules. On a challenging test set derived from PDBbind, our model improves the proportion of generated molecules with high 3D similarity to the original molecule by over 300%. In addition, DEVELOP recovers 10× more of the original molecules compared to the baseline DeLinker method. Our approach is general-purpose, readily modifiable to alternate 3D representations, and can be incorporated into other generative frameworks. Code is available at <https://github.com/oxpig/DEVELOP>.

Received 3rd May 2021  
Accepted 18th October 2021

DOI: 10.1039/d1sc02436a

[rsc.li/chemical-science](https://rsc.li/chemical-science)

## Introduction

Drug design optimises molecules through a multi-step, iterative process in order to achieve a desired biological response. The size of the search space<sup>1</sup> and discontinuous nature of the optimisation landscape<sup>2</sup> are two key factors contributing to the difficulty of this problem and, as a result, currently molecular design is typically led by human experts.

Machine learning models for molecule generation<sup>3–5</sup> offer an alternative approach to human-led design or rules-based transformations.<sup>6,7</sup> Despite recent success,<sup>8</sup> for these methods to be broadly adopted in drug discovery, more control over the generative process is required, including the ability to incorporate prior knowledge.

In the hit-to-lead (or lead generation) and lead optimisation stages of drug discovery, the goal is to improve one, or several, properties. This is typically achieved by modifying an existing molecule rather than designing a compound from scratch. Such

modifications can be broadly categorised into one of two scenarios: linker design and scaffold elaboration.

Linker design is a general problem in drug discovery capturing a wide range of tasks where the goal is to design a molecular scaffold that incorporates two (or more) specific substructures. Three key applications that can all be considered as linker design are scaffold hopping,<sup>9,10</sup> fragment linking,<sup>11,12</sup> and PROTAC design.<sup>13,14</sup> Examples of these design tasks are shown in Fig. 1a–c.

In contrast to linker design which is tasked with discovering molecular cores, scaffold elaboration proposes molecules incorporating these privileged substructures. Scaffold elaboration covers a broad range of medically important scenarios, such as R-group optimisation<sup>15</sup> and fragment growing<sup>12,16</sup> (Fig. 1d and e). R-group optimisation is utilised in almost all drug discovery projects to improve the potency, selectivity, and other properties of a molecule during lead optimisation and characterise the structure–activity relationship (SAR) of a molecular series, while growing is the primary method for elaborating fragment hits.

Recently, several deep learning methods have been proposed to address these design challenges. We previously published the first application of deep learning for molecular linker design (“DeLinker”),<sup>17</sup> reporting substantial improvement over a data-base-based approach, the previous *de facto* computational

<sup>a</sup>Oxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford OX1 3LB, UK. E-mail: [deane@stats.ox.ac.uk](mailto:deane@stats.ox.ac.uk)

<sup>b</sup>Exscientia Ltd, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE, UK

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1sc02436a






Fig. 1 Design tasks considered in this work. (a–c) cover linker design, specifically (a) scaffold hopping, (b) fragment linking, and (c) PROTAC design. (d and e) scaffold elaboration, namely (d) R-group optimisation and (e) fragment growing. Components of the ligand that are modified or added in the design process are shown in red.

method for this task, by including basic structural information. Yang *et al.*<sup>18</sup> have since proposed an alternative model (“Synta-Linker”) based on the transformer architecture and a SMILES-based representation. Their model did not incorporate structural information but instead included 1D molecular patterns capturing factors such as the shortest linker bond distance.

Deep learning approaches have also been proposed for scaffold elaboration. Graph-based approaches were proposed by Lim *et al.*<sup>19</sup> and Li *et al.*<sup>20</sup> The scaffolds employed in both methods do not have explicit attachment points. As such, these methods are primarily applicable to the general generation of molecules with a privileged scaffold or substructure, rather than tasks such as R-group design. In contrast, Arús-Pous *et al.*<sup>21</sup> developed a preprocessing formulation to permit a SMILES-based approach that requires specific attachment points to be defined.

In both linker design and scaffold elaboration, some knowledge about the desired modification is typically available;<sup>22</sup> this can either be derived from the protein binding site in the case of structure-based design,<sup>23</sup> or from other molecules in ligand-based drug discovery.<sup>24</sup> In either case, this information has strong 3D dependencies which should be taken into account. However, currently this information, which is crucial to successful compound design, is typically not utilised by generative models.<sup>25</sup>

None of the existing machine learning models for linker design or scaffold elaboration effectively utilise structural information, with DeLinker the only framework explicitly incorporating any 3D information in the form of the distance between the starting substructures and their relative orientations. While this minimal parametrization had a substantial impact on the quality of the generated molecules,<sup>17</sup> much of the key information about the characteristics of the binding site is not taken into account in the generative process.

There have been several recent approaches proposed to generate molecules from 3D representations.<sup>26–31</sup> In particular, Skalic *et al.*<sup>26</sup> generated molecules from a 3D representation of


a seed ligand. However, their approach requires a known active molecule, only provides 3D information implicitly to seed their model, and offers no further control over generated compounds. As a result, their generative model recovered fewer than 2% of seed molecules. This idea was extended in Skalic *et al.*<sup>27</sup> to generate the ligand representation from the protein target. While this alleviates the need for a known active, it is not possible to use prior knowledge to influence the ligand representation. Finally, in concurrent work to this paper, both Ragoza *et al.*<sup>28</sup> and Masuda *et al.*<sup>29</sup> generate molecules by adopting an autoencoder framework to first generate atomic densities, before using a fitting procedure to convert the continuous 3D grids to discrete molecular structures.

All prior approaches utilising 3D representations attempt to generate entire molecules and do not readily incorporate expert knowledge. While this is arguably the end-goal for molecular design, in practice this limits the applicability of such methods. In particular, it prevents their use in later stage drug discovery where there is significant prior knowledge that could and should inform compound design.

In this paper, we propose DEVELOP (DEep Vision-Enhanced Lead OPTimisation), a graph-based generative model that uses a convolutional neural network (CNN) to incorporate physically-meaningful 3D structural information, here provided as 3D pharmacophores,<sup>32</sup> a general and widely-used representation in cheminformatics. Our model is applicable to a wide variety of design tasks in the hit-to-lead and lead optimisation stages of drug discovery, covering linker design and scaffold elaboration. Importantly, the richer representation of the binding site readily and naturally allows the incorporation of domain knowledge and significantly improves the quality of generated compounds. On a challenging test set derived from PDBbind, our model improves the proportion of generated molecules with high 3D similarity to the original molecule by over 300%. In addition, DEVELOP recovers 10× more of the original molecules compared to the baseline DeLinker method.



## (a) Linker Design



## (b) Scaffold Elaboration




Fig. 2 Overview of DEVELOP. The starting structures and 3D pharmacophore map are converted into a graph representation and a voxel grid, respectively. These are fed into GNN and CNN encoders, respectively. The featurisations are combined and decoded by a GNN-based decoder.

## Methods

This work describes DEVELOP, a deep learning approach combining GNNs and CNNs for molecular linker design and scaffold elaboration. We extend current molecular generative methods to incorporate physically-meaningful 3D structural information, enabling prior knowledge to be readily incorporated and allowing greater control of the generative process by domain experts. Our underlying model is based on Imrie *et al.*,<sup>17</sup> which built on the generative process introduced by Liu *et al.*<sup>33</sup> that constructs molecules “bond-by-bond” in a breadth-first manner. Here we outline the generative process and describe how 3D structural information is incorporated (Fig. 2).

## Generative process

To perform the generative tasks considered in this manuscript, DEVELOP takes as input (i) the chemical structure of either the substructures that are to be linked or the molecular scaffold that is to be elaborated and (ii) a 3D structure of the partial molecule and the desired pharmacophoric features. The input to DEVELOP can be seen in Fig. 2 for both linker design and scaffold elaboration.

Pharmacophores are a widely-used representation in cheminformatics.<sup>32</sup> They are designed to capture the key chemical interactions that allow ligands to bind to macromolecular targets, such as hydrogen bonds, charges, or lipophilic contacts.

Pharmacophores can be derived both from other molecules (ligand-based) and inferred or proposed based on the protein target of interest (structure-based), making this representation broadly applicable. In this work, we utilised 3D pharmacophores derived from the ground truth molecules.

Due to their prevalence and importance in drug discovery, the pharmacophores included in our representation were hydrogen bond donors, hydrogen bond acceptors, and aromatic systems. Pharmacophores were determined according to the default RDKit definitions. Our framework is readily extendable to additional pharmacophores, or alternate structural representations.

To generate new molecules, first, a graph representation of the starting substructure(s) is constructed and nodes are encoded using a gated graph neural network (GGNN)<sup>34</sup> in line with Imrie *et al.*<sup>17</sup> The 3D structure of the starting molecular fragment(s) and desired pharmacophores is voxelised to construct a 3D grid, with atoms and pharmacophores adopting a Gaussian representation centered at their input coordinates<sup>35</sup> (Fig. 2). Input structures are augmented *via* random translations of up to 1.0 Å and random rotations. The voxel grid representation is passed into a 3D convolutional neural network composed of three  $3 \times 3 \times 3$  convolutional layers with ReLU activation, each followed by a  $2 \times 2 \times 2$  max pooling layer, with the final convolutional layer followed by a global max pooling operation. We then apply dropout with probability 0.2 before a fully-connected layer produces the 3D structural encoding.



For linker design, the distance and angle between the starting substructures has been shown to provide a useful constraint.<sup>17</sup> However, this representation is not readily extendable to scaffold elaboration, and thus this information is only provided for linker design. The 3D structural encoding is concatenated with the distance and angle information (in the case of linker design) and a 1D count vector representing the number of each pharmacophoric feature that should be present in the generated molecule. This forms the structural information,  $\mathbf{D}$ , used by the decoder to generate molecules.

From these embeddings, molecules are generated in line with Imrie *et al.*<sup>17</sup> The decoding process is initialised with the node encodings together with a set of expansion nodes whose feature vectors are drawn from the standard normal,  $\mathcal{N}(\mathbf{0}, \mathbf{I})$ . Each node is labeled with an atom type sampled from a classifier applied to the concatenation of the node encoding and the structural information,  $\mathbf{D}$ .

Molecules are constructed iteratively “bond-by-bond” from this set of nodes. After each step, the node encodings are updated by a decoder GGNN. Edges and their edge types are chosen based on the feature vector for the (possible) edge between node  $v$  and candidate node  $u$  given by

$$\phi_{v,u}^t = [t, s_v^t, s_u^t, d_{v,u}, \mathbf{H}^0, \mathbf{H}^t, \mathbf{D}],$$

where  $s_v^t = [\mathbf{z}_v^t, l_v]$  is the concatenation of the hidden state of node  $v$  after  $t$  steps ( $\mathbf{z}_v^t$ ) and its atomic label ( $l_v$ ),  $d_{v,u}$  is the graph distance between  $v$  and  $u$ ,  $\mathbf{H}^0$  is the average initial representation of all nodes,  $\mathbf{H}^t$  is the average representation of nodes at generation step  $t$ , and  $\mathbf{D}$  represents the structural information.

Our model is trained using the same loss function as Imrie *et al.*<sup>17</sup> which is similar to the standard VAE loss, including a reconstruction loss and a Kullback–Leibler (KL) regularisation term:

$$\mathcal{L} = \mathcal{L}_{\text{recon}} + \lambda_{\text{KL}} \mathcal{L}_{\text{KL}}.$$

No extra terms are included to regularise the CNN encoding. As a result, the CNN is trained to produce structural encodings of the input structures and pharmacophoric representation that help the network to minimize the overall loss. We use the same hyperparameters for training as Imrie *et al.*<sup>17</sup> (see ESI†). For additional details regarding the underlying model see Imrie *et al.*<sup>17</sup>

## Data sets

Due to the lack of experimental data, we constructed sets for training and evaluation from general molecular data sets using standard transformations from matched-molecular pair analysis.<sup>36</sup> For both linker design and scaffold elaboration, we used the same underlying data and adopted the same process for constructing datasets, with the main difference the transformation used. For linker design, we enumerated all double cuts of acyclic single bonds that were not within functional groups, while for scaffold elaboration we performed single cuts.

The training sets were derived from the subset of ZINC<sup>37</sup> selected at random by Gómez-Bombarelli *et al.*<sup>3</sup> using the

fragmentation procedure described above. For linker design, this results in *ca.* 418 000 fragment–molecule pairs and is the same training set as Imrie *et al.*,<sup>17</sup> while for scaffold elaboration there are *ca.* 427 000 examples.

To evaluate our method, we constructed test sets for linker design and scaffold elaboration from CASF-2016 (ref. 38) and the PDBbind Refined Set<sup>39</sup> (v. 2019) using the same fragmentation procedure used to construct the training set. For both of the CASF and PDBbind test sets, we only retained examples with elaborations containing at least five atoms. In addition, for the PDBbind test sets, we ensured that the molecular elaboration was unique and was not present in the training set. As a result, the CASF test sets contain 188 and 143 examples for linker design and scaffold elaboration, respectively, while the PDBbind test sets contain 321 and 288 examples, respectively. Due to the stricter inclusion criteria, the PDBbind test sets represent a significantly more challenging test than the CASF sets and should better capture the ability of a method to extrapolate to new linkers and elaborations.

## Evaluation metrics

We assessed the generated molecules with a range of 2D and 3D metrics, adopting a similar procedure to Imrie *et al.*<sup>17</sup> We first checked the generated molecules for validity, uniqueness, and novelty. A molecule is deemed “valid” if it contains the starting substructure(s) and its SMILES representation can be parsed by RDKit<sup>40</sup> (*i.e.*, satisfies atomic valency rules). Uniqueness measures the proportion of distinct molecules generated. Uniqueness was checked on a per-example basis to remove any dependency between examples in the test set. Novelty assesses the proportion of generated linkers or elaborations that were not present in the training set. Low novelty indicates overfitting<sup>41,42</sup> and limits the application of such models to scenarios where a novel elaboration is required. However, higher novelty is not always desirable, especially in the settings considered in this manuscript, since in many cases common elaborations found in the training set will be suitable. Formal details of the calculation of these metrics are provided in the ESI.† We then determined if the generated examples were consistent with the 2D property filters used to produce the training set. While it is likely that there are many molecules that would fulfil the desired criteria of the user, the original molecule is a “true” correct answer and represents the best single ground truth available. As a result, a primary evaluation metric was the recovery rate, which measures in how many cases the original molecule was recovered by the generation process.

Molecules which passed the 2D property filters were assessed on the basis of their 3D shape. We calculated 3D similarity by scoring conformers of the generated molecules against the original molecule using the same 3D shape and colour score utilised in Imrie *et al.*,<sup>17</sup> based on the methods described in Putta *et al.*<sup>43</sup> and Landrum *et al.*<sup>44</sup> For both linker design and scaffold elaboration, we primarily assessed the 3D complementarity of the generated molecular component only (*i.e.* the linker or R-group) with the reference structure (SC<sub>RDKit</sub> generated). This score ranges between 0 (no match) and 1 (perfect





match). Scores above 0.6 indicate a good match, while scores above 0.9 suggest an almost perfect match.

The focus of our analysis is based on  $SC_{RDKit}$  generated as it directly captures the chemical differences between the proposed molecules. However, for linker design we also calculated the 3D metrics utilised in Imrie *et al.*<sup>17</sup> ( $SC_{RDKit}$  Molecule,  $SC_{RDKit}$  Fragments, RMSD) to ensure that the proposed linkers satisfy the basic structural constraints. We did not use these metrics in the scaffold elaboration experiments since the conformation of the molecular core is typically largely unaffected by its side chains.<sup>45</sup>

For each proposed compound, we generated 3D conformers using RDKit,<sup>40</sup> adopting the filtering and sampling procedure proposed by Ebejer *et al.*<sup>46</sup> To calculate  $SC_{RDKit}$  generated, we generated conformers in a constrained manner, biasing conformations towards those that maintained the conformation of the starting structure(s). However, to mitigate the risk of generating physically unrealistic structures, we removed high energy conformers. We then scored all conformers, taking the best score as the final score for a particular molecule.

### Comparison to other methods

For both linker design and scaffold elaboration, we compared DEVELOP to DeLinker<sup>17</sup> and a version of the DeLinker method which is provided with the number of each pharmacophoric feature that should be present in the generated linker ("DeLinker-Counts"). The difference between DEVELOP and these two baselines is the structural information,  $D$ , included in the feature vector,  $\phi_{v,u}^t$ . This comparison allowed us to assess directly the impact of (1) including pharmacophoric constraints, and (2) providing these constraints as a physically-meaningful 3D structural representation rather than a 1D count vector.

We also compared our results to recent deep learning methods for these design problems. For linker design, we compared our method to SyntaLinker,<sup>18</sup> while for scaffold elaboration, we benchmarked against Arús-Pous *et al.*<sup>21</sup> ("Scaffold-Decorator"). Both methods adopt a SMILES-based formulation and neither framework incorporates 3D information in the design process. In both cases, we retrained these models on the training sets described above using the open-source implementations provided by the authors to ensure a fair comparison between the methods tested. We adopted the same settings and hyperparameters described in the original publications. The only deviation was the sampling strategy employed for SyntaLinker: in the main manuscript, we report results using a sampling-based strategy; we have included a comparison between beam search and random sampling in the ESI.†

### Experimental setup

In all of our experiments, we used the same training sets (one for linker design and one for scaffold elaboration) derived from the ZINC data set to train all of the models considered. When evaluating using the data sets derived from CASF and PDBbind, we generated 250 molecules for each example for each of the methods considered. For the graph-based models (DeLinker, DeLinker-Counts, and DEVELOP), the number of atoms was set

equal to the number of atoms in the original molecule. The pharmacophoric information provided to DeLinker-Counts and DEVELOP was derived directly from the ground truth molecule. In the case of SyntaLinker, the model was provided with the shortest linker bond distance.

## Results and discussion

We validate the ability of our deep generative model (DEVELOP) to perform linker design and scaffold elaboration using 3D pharmacophoric information, reporting significant improvement over all other methods. Through the use of several canonical examples, we demonstrate the impact of the pharmacophoric constraints on the generated molecules. Several examples of generated molecular groups can be found in Fig. 3. We show a significant improvement in the quality of generated molecules in large-scale evaluations on test sets derived from CASF and PDBbind, further demonstrating the importance of including pharmacophoric information. Finally, we illustrate the applicability of our approach to scaffold elaboration using an R-group optimisation case study derived from the literature.

### Importance of 3D pharmacophoric constraints

We assessed the impact of pharmacophoric constraints on the generation process empirically using two canonical examples for linker design and one example for scaffold elaboration (Table 1). The examples were all chosen from the PDBbind test sets (see Methods) and therefore none of the target elaborations were included in the training set. We generated 1000 molecules for each example using DeLinker, DeLinker-Counts, and DEVELOP.

Only DEVELOP was able to recover both of the canonical examples for linker design, with DeLinker not generating the correct linker in either case. The difference between the methods is further exemplified when considering geometric isomers with the same chemical structure but possibly different substitution patterns of the exit vectors and substituent. DEVELOP frequently generated linkers matching the chemical structure of the linker (41–47), while DeLinker did not produce a single geometric isomer.


The improved performance of DEVELOP is also evident when we assessed how many molecules included the desired pharmacophoric pattern of the examples (aromatic ring with correct substituent group). A significantly larger proportion of the generated molecules contained the desired pharmacophoric features when the 3D information was provided (60–148, DEVELOP) compared to not providing this information (13–14, DeLinker) or providing only 1D pharmacophore counts (12–19, DeLinker-Counts).

The largest difference in generated molecules occurred in the phenol example, where only one geometric isomer was generated by DeLinker and DeLinker-Counts combined compared to 41 from DEVELOP. This is a particularly difficult example for both DeLinker and DeLinker-Counts due to the presence of a donor–acceptor group, but illustrates the necessity of adopting a 3D representation.



**Table 1** Impact of pharmacophoric constraints. Including 3D pharmacophoric information (DEVELOP) substantially improves the ability to generate molecules with desired interaction patterns

Design task	PDB ID	Target elaboration	Method	Recovered	No. geometric isomers	No. include pharmacophores
Linker design	2FLR		DeLinker	No	0	14
			DeLinker-Counts	No	1	12
			DEVELOP	Yes	41	148
	5IWG		DeLinker	No	0	13
			DeLinker-Counts	Yes	16	19
			DEVELOP	Yes	47	60
Scaffold elaboration	3HB4		DeLinker	No	0	0
			DeLinker-Counts	No	0	0
			DEVELOP	Yes	3	7



**Fig. 3** Common functional groups, their pharmacophoric representations, and example molecules generated by DEVELOP. Several of the most common functional groups<sup>47</sup> contained in the test sets were selected. The pharmacophoric representation for these examples together with several of the molecules that were most frequently generated by DEVELOP are shown. (a and b) Linker design: (a) amide (PDB ID 4GID), (b) aniline (PDB ID 5IWG); (c and d) Scaffold elaboration: (c) amide (PDB ID 3P5O), (d) sulfone (PDB ID 4QD6).

The scaffold elaboration example proved challenging for all methods, primarily due to the size of the elaboration. Only DEVELOP recovered the 3-methyl-benzamide elaboration, with neither of the other two methods generating a single geometric isomer. In addition, DEVELOP was the only method to generate any elaborations containing the desired functionality of an aromatic system with an amide side-chain.

These examples demonstrate the importance of including pharmacophoric constraints for both linker design and scaffold elaboration. In all cases, it was only possible to consistently generate molecules with specific pharmacophoric profiles when 3D pharmacophoric information was included.

#### Linker design experiments on large test sets

DEVELOP substantially outperformed all other methods on both the CASF and PDBbind test sets, with significant

improvements in both the number of true linkers recovered and the proportion of generated molecules with high  $SC_{RDKit}$  generated. This was achieved with limited impact on the uniqueness of the generated molecules and their ability to pass basic 2D chemical filters (Tables 2, S4† and Fig. 4).

In comparison, SyntaLinker performed poorly in particular as measured by the 2D metrics, producing weaker results than were reported in its original publication.<sup>18</sup> SyntaLinker produced a low proportion of valid, unique, and novel molecules, and did not recover any of the original molecules in the PDBbind test set. Due to the comparatively weak results, we focus the remainder of our analysis on the three graph-based methods. For further discussion regarding SyntaLinker and additional results, see the ESI.†

The proportion of valid molecules generated by the other three methods was high in all cases (>90%) with similar proportions of novel molecules proposed (69–71% on CASF,



**Table 2** Linker design. PDBbind set results (see Methods, Evaluation metrics for definitions of the metrics)

Metric	SyntaLinker	DeLinker	DeLinker-Counts	DEVELOP
Valid	65.4%	96.9%	90.2%	93.1%
Unique	9.0%	86.1%	77.8%	77.3%
Novel	9.9%	84.0%	87.6%	88.7%
Recovered	0.0%	1.9%	8.7%	22.4%
Pass 2D filters	95.1%	63.4%	59.5%	61.7%
<b>SC<sub>RDKit</sub> generated</b>				
>0.6	13.4%	10.4%	19.8%	27.9%
>0.7	7.7%	4.2%	10.1%	14.8%
>0.8	4.8%	1.5%	4.4%	6.1%
>0.9	1.3%	0.4%	1.2%	1.5%

Table S4;† 84–89% on PDBbind, Table 2). As is expected, as more structural information was provided to the model, the proportion of unique molecules decreased due to the constraints on the generative process. However, 58% and 77% of the molecules produced by DEVELOP on CASF and PDBbind, respectively, were unique, demonstrating that the model still samples from chemical space and has not experienced mode collapse, degrading to a single or small number of solutions.

Incorporating pharmacophoric information substantially increased the recovery rate of the original molecules. On the CASF set, DEVELOP recovered 50% of the ground truth molecules, compared to 30% for DeLinker and 42% for DeLinker-Counts. The PDBbind set is particularly challenging with DeLinker only able to recover 1.9% of the original molecules, while a database-based method would not be able to recover any, due to there being no overlap with the training set. Including the count of each pharmacophore present in the original linker increased the proportion recovered to 8.7% (DeLinker-Counts). Crucially, providing this information as a 3D structural representation offered a significant benefit over simply providing the pharmacophore counts. On the PDBbind test set, DEVELOP recovered 22.4% of the original molecules, more than ten times as many as DeLinker and more than twice as many as DeLinker-Counts (Table 2).

A significant improvement is also seen when assessing the 3D similarity of the generated linkers to the original ones. DEVELOP improved the proportion of molecules with high structural similarity (SC<sub>RDKit</sub> generated >0.8) by 300% and 39% compared to DeLinker and DeLinker-Counts, respectively, on the PDBbind test set (Table 2), with similar improvements on the CASF set (Table S4†).


In addition to SC<sub>RDKit</sub> generated, we also calculated the 3D metrics employed in Imrie *et al.*,<sup>17</sup> namely SC<sub>RDKit</sub> Molecule, SC<sub>RDKit</sub> Fragments, and RMSD. These metrics primarily capture whether the molecular linker allows the original substructures to adopt similar conformations, with the chemical features of the linker having limited to no effect on this score. The linkers generated by DEVELOP showed a substantial improvement on CASF compared to both DeLinker and DeLinker-Counts (Table S5†), while performing similarly on PDBbind (Table S6†).

As previously stated, these metrics primarily assess whether the linker can allow the starting substructures to adopt the required conformation. The additional information regarding the desired linker chemistry may well not improve these scores, even when linker quality is substantially improved.

To investigate whether the improvement in recovery rate is due to the number of linkers generated, we generated 5000 examples for each pair of starting fragments and assessed in how many cases the true linker was recovered (Fig. 4). The improvement in recovery rate of DEVELOP persisted even as substantially more linkers were generated. After several thousand examples, the rate of recovery of additional linkers decreased significantly for all methods, but remained the highest for DEVELOP. While increasing the number of samples further would be likely to yield more linkers being recovered, this effect may well be relatively small unless orders of magnitude more samples were generated. Fig. 4 demonstrates that DEVELOP generates better linkers rather than simply producing similar molecules to DeLinker.

#### Scaffold elaboration experiments on large test sets

Large-scale assessments on the CASF and PDBbind test sets demonstrated that DEVELOP can effectively perform scaffold



**Fig. 4** Linker design. Number of original molecules recovered as the number of generated molecules is increased. DEVELOP recovers the significantly more of the original molecules than both baselines for any number of samples generated.



Table 3 Scaffold elaboration. PDBbind set results (see Methods, Evaluation metrics for definitions of the metrics)

Metric	Scaffold-Decorator	DeLinker	DeLinker-Counts	DEVELOP
Valid	99.9%	100.0%	100.0%	99.5%
Unique	23.4%	87.8%	81.6%	76.2%
Novel	2.0%	71.1%	79.2%	78.2%
Recovered	0.0%	1.0%	4.5%	15.3%
Pass 2D filters	98.9%	55.3%	47.8%	51.3%
<b>SC<sub>RDKit</sub> generated</b>				
>0.6	4.3%	2.6%	4.6%	12.0%
>0.7	0.9%	0.7%	1.3%	4.3%
>0.8	0.3%	0.1%	0.4%	0.9%
>0.9	0.0%	0.0%	0.2%	0.1%

elaboration, with similar trends as the linker design experiments (Tables 3, S7† and Fig. 5).

Almost all molecules generated by the graph-based models (DeLinker, DeLinker-Counts, and DEVELOP) are deemed valid since chemical valency is enforced during generation (the very small number of invalid molecules arises from cases where no elaboration is proposed, Table 3). The majority of molecules generated were unique, with uniqueness decreasing from 88% for DeLinker to 76% for DEVELOP as more constraints were provided. This was in line with expectations and mirrors the linker design experiments, with all methods proposing a high proportion of novel R-groups (43–55% on the CASF set, 71–79% on the PDBbind set).

In line with the performance for linker design, including 3D pharmacophoric information resulted in a substantially higher proportion of the true elaborations being recovered. On the CASF test set, DEVELOP recovered 59% of the ground truth molecules compared to 34% for DeLinker and 45% for DeLinker-Counts (Table S7†). On the PDBbind set, DEVELOP recovered 15% of the original elaborations, an increase of more than ten-fold compared to DeLinker (1.0%, Table 3). This performance persisted as more molecules were generated (Fig. 5). When 5000 elaborations were generated for each scaffold, DEVELOP recovered 35% of the original molecules

compared to 16% when the 3D information was removed (DeLinker-Counts) and only 7% when no pharmacophoric information was included (DeLinker).

Finally, there was a substantial improvement in the 3D similarity of the generated molecules to the original ones. Of the elaborations which passed the 2D filters, 12.0% of those generated by DEVELOP obtained an SC<sub>RDKit</sub> generated score of greater than 0.6 compared to 2.7% and 4.6% obtained by DeLinker and DeLinker-Counts, respectively.

Almost none of the molecules generated by any method for the PDBbind test set achieved an SC<sub>RDKit</sub> generated score above 0.9. To reduce the impact of possible limitations of the conformer generation process, we recalculated SC<sub>RDKit</sub> generated using generated conformers of the ground truth molecules instead of the experimentally determined conformers (Tables S9 and S8†). On the PDBbind set, the proportion of generated molecules with SC<sub>RDKit</sub> generated >0.9 remained low for all methods except DEVELOP, which increased to 1.5%. This represents a sizeable improvement over the next best method (DeLinker-Counts, 0.3%) and provides further validation of the improved quality of molecules generated by DEVELOP compared to the baselines.

Scaffold-Decorator produced significantly fewer novel elaborations than either of the DeLinker models or DEVELOP, with




Fig. 5 Scaffold elaboration. Number of original molecules recovered as the number of generated molecules is increased. DEVELOP recovers the significantly more of the original molecules than both baselines for any number of samples generated.





only 2–3% of generated elaborations not contained in the training set (Tables 3 and S7†). As such, Scaffold-Decorator did not recover any of the original elaborations in the PDBbind test set, while on the CASF test set Scaffold-Decorator recovered only 19% of the original elaborations compared to 58% for DEVELOP. In addition, Scaffold-Decorator generated a similar proportion of elaborations that had high 3D similarity to the original molecules as DeLinker, and was substantially outperformed by both DeLinker-Counts and DEVELOP. This is expected given the additional information available to both models; however, it reinforces the importance of including pharmacophoric information.

### R-group optimisation case study

We further demonstrate the applicability of DEVELOP to R-group optimisation *via* a case study derived from the literature. Borkin *et al.*<sup>48</sup> developed a thienopyrimidine class of compounds to block the protein–protein interaction between menin and mixed lineage leukemia (MLL) fusion proteins. This interaction plays an important role in acute leukemias with MLL translocations, making this an important drug target. The authors' previous work<sup>49</sup> had led to the identification of a highly potent menin–MLL inhibitor ( $IC_{50} = 31$  nM,  $GI_{50} = 0.55$   $\mu$ M, PDB ID: 4X5Z) but required further improvement of cellular activity and drug-like properties to develop compounds with potential therapeutic value. This was achieved *via* structure-based optimisation of substituents introduced to the indole ring (Fig. 6a).

Following optimisation of several positions, the most potent compound displayed almost a seven-fold improvement in affinity in MLL-AF9 cells ( $GI_{50} = 83$  nM, PDB ID: 5DB3, Fig. 6b, right), while other highly potent compounds demonstrated favourable drug-like properties, such as significant improvements in selectivity, reduced lipophilicity, and bioavailability.

The most significant modification to the original compound was the optimisation of the hydrogen bond interactions with Glu363 and Glu366 on menin. The indole nitrogen in the original molecule was involved in a hydrogen bond with the side chain of Glu363 but was partially solvent exposed and was not forming interactions with Glu366 (Fig. 6a). This led the authors to explore a variety of substituents containing hydrogen bond donors. Two potent substitutions were an acetamide group (Fig. 6b, left) and 4-methylpyrazole (Fig. 6b, right).

We investigated the ability of DEVELOP to propose R-groups that met the design hypothesis described in Borkin *et al.*<sup>48</sup> In particular, we sought to design both aromatic and non-aromatic hydrogen bond donor groups that were able to make similar interactions to the R-groups that were experimentally tested. We derived 3D pharmacophoric profiles from the ligands in PDB IDs 5DB2 and 5DB3 to serve as input to DEVELOP. For the pharmacophoric profile derived from 5DB2, we generated 1000 R-groups with a maximum of four, five, and six atoms, whilst for the pharmacophoric profile derived from 5DB3 we generated 1000 molecules with a maximum of five, six, and seven atoms.

DEVELOP successfully recovered both of the experimentally-verified R-groups while generating many alternative molecules




Fig. 6 R-group optimisation case study. (a) Crystal structure (PDB ID 4X5Z) of the initial complex bound to menin. (b) Structure of two of the most potent optimised compounds (PDB IDs left 5DB2, right 5DB3). The dashed lines represent key interactions. (c) Overlay of the most potent optimised compound (green carbons, PDB ID 5DB3) and several compounds generated by DEVELOP (yellow carbons) that make similar hydrogen bonding interactions (dashed lines).

that could form similar interactions with menin. All methods were able to recover the acetamide R-group (Fig. 6b, left). However, DEVELOP produced substantially more examples that matched the pharmacophoric profile (455) compared to both DeLinker-Counts (327) and DeLinker (103). All methods were also able to recover the 4-methylpyrazole R-group, although this elaboration was only generated once by DeLinker and DeLinker-Counts, compared to 61 times by DEVELOP. While generating the same molecule a large number of times is not necessarily desirable, the increased frequency of generation of the ground truth elaboration in this case has several benefits. First, the true R-group is one of a limited number of elaborations that matches the pharmacophores. Thus when this constraint is provided to the model, we would hope that it generates molecules that meet this constraint more frequently. Second, since all three generative models are stochastic, if a given molecule is only generated a small number of times, there is the possibility this is due to chance and this molecule would not be discovered in another instance. To exemplify this point, we repeated the generation step for the case study 10 times for each method and calculated in how many cases we recovered the 4-methylpyrazole R-group. In all cases, DEVELOP recovered the ground truth molecule, whereas DeLinker and DeLinker-Counts only recovered the ground truth in 5/10 and 4/10 cases, respectively. Finally, we note that DEVELOP generated this elaboration with an overall frequency of *ca.* 2% (61/3000), which represents a small fraction of all generated molecules. In addition, 237 of the elaborations generated by DEVELOP contained an aromatic system with a donor group linked to the indole *via* a methylene group compared to 50 for DeLinker and 11 for DeLinker-Counts.

We next sought to assess the alternatives to the pyrazole R-group (Fig. 6b, right) that were proposed by DEVELOP. To validate the molecules proposed by DEVELOP, we docked the generated molecules containing an aromatic system and at least one donor group using GOLD<sup>50</sup> and checked whether the docked pose formed hydrogen bonding interactions with Glu363 or Glu366. Three elaborations, together with their Murcko scaffolds, are shown in Fig. 6c (yellow carbons) overlaid with the pyrazole R-group (green carbons). All of the examples appear to fit within the pocket and were able to form hydrogen bonds with Glu363 or Glu366, consistent with the stated design hypothesis.

Finally, we scored the generated molecules which satisfied the specified pharmacophoric profiles using the *smi*<sup>51</sup> version of AutoDock Vina.<sup>52</sup> For the first pharmacophoric profile, around one third of the molecules proposed by all methods obtained a predicted binding affinity greater than or equal to the corresponding ground truth elaboration, leading to DEVELOP proposing 152 such molecules, DeLinker 34 and DeLinker-Counts 115 (Fig. S8†). For the second pharmacophoric profile, DEVELOP (171 from 237) significantly more often (both as a proportion and in absolute terms) proposed molecules which satisfied the second pharmacophoric profile and had a predicted binding affinity at least as great as the ground truth compared to DeLinker (17 from 50) and DeLinker-Counts (5 from 11) (Fig. S9†).

## Conclusion

We have developed a method that combines GNNs with CNNs to incorporate 3D pharmacophoric constraints into molecular generation. Our approach allows prior knowledge to be used to control the design process and is readily extendable to alternate 3D structural representations.

We have demonstrated the applicability of our approach to both linker design and scaffold elaboration, two general tasks in the hit-to-lead and lead optimisation stages of drug discovery.

The experimental results show that our model significantly outperforms previous methods for these problems and demonstrates the power of including pharmacophoric constraints as a 3D representation as opposed to a 1D count vector.

While the quality of the generated compounds has increased significantly, the problem of selecting which ones should be explored further remains a key consideration. Successful application of generative models relies on their successful integration into the broader drug discovery toolbox. An interesting development in this direction is described in Green *et al.*,<sup>53</sup> who used CNNs to predict appropriate fragments given the structure of a protein–ligand complex. While their work was based on scoring a fixed database of fragments, extending such an approach to assess arbitrary elaborations could be readily combined with our method to rank generated molecules.

While the focus of our work is generating molecules with specific 3D characteristics, we do not directly assign atomic coordinates during generation. The direct generation of 3D molecular structures is an exciting development,<sup>54,55</sup> but has only recently begun to be applied to drug-like molecules<sup>56</sup> while existing methods are not directly applicable to the settings considered in this work. Extending our framework to generate atomic coordinates directly is an avenue for future work. Similarly, while we have shown encoding graph- and voxel-based representations separately is effective, unifying both with a single encoder that is 3D-aware could provide further benefit. Voxel grids also have limitations stemming from their inherent approximation of 3D structures and, when coupled with standard CNNs, are not translational or rotation invariant. Although measures such as random translations and rotations can largely mitigate these effects, future work could incorporate techniques to eliminate such effects entirely (*e.g.* Thomas *et al.*,<sup>57</sup> Fuchs *et al.*<sup>58</sup>).

Finally, the pharmacophoric profiles used for our experiments were extracted from known molecules. While existing molecules can often be used as the basis for specifying desired pharmacophoric profiles in scaffold hopping or R-group optimisation, for fragment linking or elaboration a suitable ligand might not be available to derive a pharmacophoric profile, necessitating the manual specification of pharmacophoric features by a human expert. Accurate prediction of useful pharmacophoric features, directly from the protein structure or by other means, is therefore an important next step.

## Data availability

We believe that our method will allow greater synergy between human design hypotheses and machine learning-based



molecular design. Code is available at <https://github.com/oxpig/DEVELOP>.

## Author contributions

F. I., A. R. B., and C. M. D. conceptualised and designed the study. All authors contributed to the methodology of the study. F. I. implemented the method. F. I. and T. E. H. conducted the experiments and analysed the results. A. R. B. and C. M. D. supervised the project. All authors contributed to the writing, review, and editing of the manuscript.

## Conflicts of interest

There are no conflicts of interest to declare.

## Acknowledgements

F. I. is supported by funding from the Engineering and Physical Sciences Research Council (EPSRC) and Exscientia (Reference: EP/N509711/1). T. E. H. is supported by funding from EPSRC, LifeArc, F. Hoffmann-La Roche AG, and UCB Pharma (Reference: EP/L016044/1).

## References

- 1 P. G. Polishchuk, T. I. Madzhidov and A. Varnek, Estimation of the Size of Drug-Like Chemical Space Based on GDB-17 Data, *J. Comput.-Aided Mol. Des.*, 2013, **27**, 675–679.
- 2 D. Stumpfe and J. Bajorath, Exploring Activity Cliffs in Medicinal Chemistry, *J. Med. Chem.*, 2012, **55**, 2932–2942.
- 3 R. Gómez-Bombarelli, J. N. Wei, D. Duvenaud, J. M. Hernández-Lobato, B. Sánchez-Lengeling, D. Sheberla, J. Aguilera-Iparraguirre, T. D. Hirzel, R. P. Adams and A. Aspuru-Guzik, Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules, *ACS Cent. Sci.*, 2018, **4**, 268–276.
- 4 M. H. S. Segler, T. Kogej, C. Tyrchan and M. P. Waller, Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks, *ACS Cent. Sci.*, 2018, **4**, 120–131.
- 5 W. Jin, R. Barzilay and T. S. Jaakkola, Junction Tree Variational Autoencoder for Molecular Graph Generation, *International Conference on Machine Learning (ICML)*, 2018, vol. 80, pp. 2323–2332.
- 6 N. Brown, B. McKay, F. Gilardoni and J. Gasteiger, A Graph-Based Genetic Algorithm and Its Application to the Multiobjective Evolution of Median Molecules, *J. Chem. Inf. Comput. Sci.*, 2004, **44**, 1079–1087.
- 7 J. Besnard, G. F. Ruda, V. Setola, K. Abecassis, R. M. Rodriguez, X.-P. Huang, S. Norval, M. F. Sassano, A. I. Shin, L. A. Webster, F. R. C. Simeons, L. Stojanovski, A. Prat, N. G. Seidah, D. B. Constam, G. R. Bickerton, K. D. Read, W. C. Wetsel, I. H. Gilbert, B. L. Roth and A. L. Hopkins, Automated Design of Ligands to Polypharmacological Profiles, *Nature*, 2012, **492**, 215–220.
- 8 A. Zhavoronkov, Y. A. Ivanenkov, A. Aliper, M. S. Veselov, V. A. Aladinskiy, A. V. Aladinskaya, V. A. Terentiev, D. A. Polykovskiy, M. D. Kuznetsov, A. Asadulaev, Y. Volkov, A. Zholus, R. R. Shayakhmetov, A. Zhebrak, L. I. Minaeva, B. A. Zagribelnyy, L. H. Lee, R. Soll, D. Madge, L. Xing, T. Guo and A. Aspuru-Guzik, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, *Nat. Biotechnol.*, 2019, **37**, 1038–1040.
- 9 H.-J. Böhm, A. Flohr and M. Stahl, Scaffold Hopping, *Drug Discovery Today: Technol.*, 2004, **1**, 217–224.
- 10 S. R. Langdon, P. Ertl and N. Brown, Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization, *Mol. Inf.*, 2010, **29**, 366–385.
- 11 O. Ichihara, J. Barker, R. J. Law and M. Whittaker, Compound Design by Fragment-Linking, *Mol. Inf.*, 2011, **30**, 298–306.
- 12 R. J. Bienstock, in *Fragment-Based Methods in Drug Discovery*, ed. A. E. Klon, Springer New York, New York, NY, 2015, pp. 119–135.
- 13 R. I. Troup, C. Fallan and M. G. J. Baud, Current strategies for the design of PROTAC linkers: a critical review, *Explor. Targeted Anti-Tumor Ther.*, 2020, **1**, 273–312.
- 14 J. Li and J. Liu, PROTAC: A Novel Technology for Drug Development, *ChemistrySelect*, 2020, **5**, 13232–13247.
- 15 R. Guha, in *In Silico Models for Drug Discovery*, ed. S. Kortagere, Humana Press, Totowa, NJ, 2013, pp. 81–94.
- 16 B. Lamoree and R. E. Hubbard, Current Perspectives in Fragment-Based Lead Discovery (FBLD), *Essays Biochem.*, 2017, **61**, 453–464.
- 17 F. Imrie, A. R. Bradley, M. van der Schaar and C. M. Deane, Deep Generative Models for 3D Linker Design, *J. Chem. Inf. Model.*, 2020, **60**, 1983–1995.
- 18 Y. Yang, S. Zheng, S. Su, C. Zhao, J. Xu and H. Chen, SyntaLinker: automatic fragment linking with deep conditional transformer neural networks, *Chem. Sci.*, 2020, **11**, 8312–8322.
- 19 J. Lim, S.-Y. Hwang, S. Moon, S. Kim and W. Y. Kim, Scaffold-based molecular design with a graph generative model, *Chem. Sci.*, 2020, **11**, 1153–1164.
- 20 Y. Li, J. Hu, Y. Wang, J. Zhou, L. Zhang and Z. Liu, DeepScaffold: A Comprehensive Tool for Scaffold-Based De Novo Drug Discovery Using Deep Learning, *J. Chem. Inf. Model.*, 2020, **60**, 77–91.
- 21 J. Arús-Pous, A. Patronov, E. J. Bjerrum, C. Tyrchan, J.-L. Reymond, H. Chen and O. Engkvist, SMILES-Based Deep Generative Scaffold Decorator for De-Novo Drug Design, *J. Cheminf.*, 2020, **12**, 38.
- 22 G. Papadatos and N. Brown, In silico applications of bioisosterism in contemporary medicinal chemistry practice, *Wiley Interdiscip. sRev.: Comput. Mol. Sci.*, 2013, **3**, 339–354.
- 23 A. C. Anderson, The Process of Structure-Based Drug Design, *Chem. Biol.*, 2003, **10**, 787–797.
- 24 G. Sliwoski, S. Kothiwale, J. Meiler and E. W. Lowe, Computational Methods in Drug Discovery, *Pharmacol. Rev.*, 2014, **66**, 334–395.





- 25 X. Xia, J. Hu, Y. Wang, L. Zhang and Z. Liu, Graph-based generative models for de Novo drug design, *Drug Discovery Today: Technol.*, 2020, **32–33**, 45–53.
- 26 M. Skalic, J. Jiménez, D. Sabbadin and G. De Fabritiis, Shape-Based Generative Modeling for De Novo Drug Design, *J. Chem. Inf. Model.*, 2019, **59**, 1205–1214.
- 27 M. Skalic, D. Sabbadin, B. Sattarov, S. Sciabola and G. De Fabritiis, From Target to Drug: Generative Modeling for the Multimodal Structure-Based Ligand Design, *Mol. Pharm.*, 2019, **16**, 4282–4291.
- 28 M. Ragoza, T. Masuda and D. R. Koes, Learning a Continuous Representation of 3D Molecular Structures with Deep Generative Models, *NeurIPS Workshop on Machine Learning for Structural Biology*, 2020.
- 29 T. Masuda, M. Ragoza and D. R. Koes, *Generating 3D Molecular Structures Conditional on a Receptor Binding Site with Deep Generative Mode*, 2020.
- 30 T. Aumentado-Armstrong, Latent molecular optimization for targeted therapeutic design, arXiv preprint arXiv:1809.02032, 2018.
- 31 M. Xu, T. Ran and H. Chen, De Novo Molecule Design Through the Molecular Generative Model Conditioned by 3D Information of Protein Binding Sites, *J. Chem. Inf. Model.*, 2021, **61**, 3240–3254.
- 32 D. Schaller, D. Šribar, T. Noonan, L. Deng, T. N. Nguyen, S. Pach, D. Machalz, M. Bermudez and G. Wolber, Next generation 3D pharmacophore modeling, *Wiley Interdiscip. Rev. Comput. Mol. Sci.*, 2020, **10**, e1468.
- 33 Q. Liu, M. Allamanis, M. Brockschmidt and A. Gaunt, Constrained Graph Variational Autoencoders for Molecule Design, *Advances in Neural Information Processing Systems 31*, (NeurIPS), 2018, pp. 7795–7804.
- 34 Y. Li, D. Tarlow, M. Brockschmidt and R. Zemel, Gated Graph Sequence Neural Networks, *International Conference on Learning Representations (ICLR)*, 2016.
- 35 J. Sunseri and D. R. Koes, libmolgrid: Graphics Processing Unit Accelerated Molecular Gridding for Deep Learning Applications, *J. Chem. Inf. Model.*, 2020, **60**, 1079–1084.
- 36 J. Hussain and C. Rea, Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets, *J. Chem. Inf. Model.*, 2010, **50**, 339–348.
- 37 T. Sterling and J. J. Irwin, ZINC 15 – Ligand Discovery for Everyone, *J. Chem. Inf. Model.*, 2015, **55**, 2324–2337.
- 38 M. Su, Q. Yang, Y. Du, G. Feng, Z. Liu, Y. Li and R. Wang, Comparative Assessment of Scoring Functions: The CASF-2016 Update, *J. Chem. Inf. Model.*, 2019, **59**, 895–913.
- 39 Z. Liu, M. Su, L. Han, J. Liu, Q. Yang, Y. Li and R. Wang, Forging the Basis for Developing Protein–Ligand Interaction Scoring Functions, *Acc. Chem. Res.*, 2017, **50**, 302–309.
- 40 G. Landrum, *RDKit: Open-Source Cheminformatics*, <http://www.rdkit.org/>, accessed November 4, 2019.
- 41 N. Brown, M. Fiscato, M. H. S. Segler and A. C. Vaucher, GuacaMol: Benchmarking Models for De Novo Molecular Design, *J. Chem. Inf. Model.*, 2019, **59**, 1096–1108.
- 42 D. Polykovskiy, A. Zhebrak, B. Sanchez-Lengeling, S. Golovanov, O. Tatanov, S. Belyaev, R. Kurbanov, A. Artamonov, V. Aladinskiy, M. Veselov, A. Kadurin, S. Johansson, H. Chen, S. Nikolenko, A. Aspuru-Guzik and A. Zhavoronkov, Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models, *Front. Pharmacol.*, 2020, **11**, 1931.
- 43 S. Putta, G. A. Landrum and J. E. Penzotti, Conformation Mining: An Algorithm for Finding Biologically Relevant Conformations, *J. Med. Chem.*, 2005, **48**, 3313–3318.
- 44 G. A. Landrum, J. E. Penzotti and S. Putta, Feature-map Vectors: A New Class of Informative Descriptors for Computational Drug Discovery, *J. Comput.-Aided Mol. Des.*, 2006, **20**, 751–762.
- 45 S. Malhotra and J. Karanicolas, When Does Chemical Elaboration Induce a Ligand To Change Its Binding Mode?, *J. Med. Chem.*, 2017, **60**, 128–145.
- 46 J.-P. Ebejer, G. M. Morris and C. M. Deane, Freely Available Conformer Generation Methods: How Good Are They?, *J. Chem. Inf. Model.*, 2012, **52**, 1146–1158.
- 47 P. Ertl, E. Altmann and J. M. McKenna, The Most Common Functional Groups in Bioactive Molecules and How Their Popularity Has Evolved over Time, *J. Med. Chem.*, 2020, **63**, 8408–8418.
- 48 D. Borkin, J. Pollock, K. Kempinska, T. Purohit, X. Li, B. Wen, T. Zhao, H. Miao, S. Shukla, M. He, D. Sun, T. Cierpicki and J. Grembecka, Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein–Protein Interaction between Menin and Mixed Lineage Leukemia (MLL), *J. Med. Chem.*, 2016, **59**, 892–913.
- 49 D. Borkin, S. He, H. Miao, K. Kempinska, J. Pollock, J. Chase, T. Purohit, B. Malik, T. Zhao, J. Wang, B. Wen, H. Zong, M. Jones, G. Danet-Desnoyers, M. Guzman, M. Talpaz, D. Bixby, D. Sun, J. Hess, A. Muntean, I. Maillard, T. Cierpicki and J. Grembecka, Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo, *Cancer Cell*, 2015, **27**, 589–602.
- 50 M. L. Verdonk, J. C. Cole, M. J. Hartshorn, C. W. Murray and R. D. Taylor, Improved protein–ligand docking using GOLD, *Proteins: Struct., Funct., Bioinf.*, 2003, **52**, 609–623.
- 51 D. R. Koes, M. P. Baumgartner and C. J. Camacho, Lessons Learned in Empirical Scoring with smina From the CSAR 2011 Benchmarking Exercise, *J. Chem. Inf. Model.*, 2013, **53**, 1893–1904.
- 52 O. Trott and A. Olson, AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization and Multithreading, *J. Comput. Chem.*, 2010, **31**, 455–461.
- 53 H. Green, D. R. Koes and J. D. Durrant, DeepFrag: A Deep Convolutional Neural Network for Fragment-based Lead Optimization, *Chem. Sci.*, 2021, **12**, 8036–8047.
- 54 N. W. A. Gebauer, M. Gastegger and K. T. Schütt, Generating equilibrium molecules with deep neural networks. *NeurIPS Workshop on Machine Learning for Molecules and Materials*, 2018.
- 55 N. Gebauer, M. Gastegger and K. Schütt, Symmetry-adapted generation of 3D point sets for the targeted discovery of molecules, *Advances in Neural Information Processing Systems 32*, 2019, pp. 7566–7578.





- 56 Y. Li, J. Pei and L. Lai, Learning to design drug-like molecules in three-dimensional space using deep generative models, arXiv preprint arXiv:2104.08474, 2021.
- 57 N. Thomas, T. Smidt, S. Kearnes, L. Yang, L. Li, K. Kohlhoff and P. Riley, Tensor field networks: Rotation-and translation-equivariant neural networks for 3d point clouds, arXiv preprint arXiv:1802.08219, 2018.
- 58 F. Fuchs, D. Worrall, V. Fischer and M. Welling, SE(3)-Transformers: 3D Roto-Translation Equivariant Attention Networks, *Advances in Neural Information Processing Systems*, 2020, pp. 1970–1981.

